search
Back to results

LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts (LISTEN)

Primary Purpose

Hypercholesterolemia With Concomitant Type 2 Diabetes

Status
Completed
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Atorvastatin
Rosuvastatin
Sponsored by
Listen Trial Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypercholesterolemia With Concomitant Type 2 Diabetes

Eligibility Criteria

20 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Hypercholesterolemia patients

    • Patients who have not achieved the target control levels of LDL-C in the "Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007"

  2. Type 2 diabetes patients

    • Patients diagnosed with type 2 diabetes and receiving diet therapy, exercise therapy, or medication
    • Patients who received constant therapy for three months before registration and have no plan for therapy change
    • Patients with kept HbA1c level (Japan Diabetes Society [JDS] level) of less than 7.0% (or, National Glycohemoglobin Standardization Program [NGSP] level of less than 7.4%) within three months before registration
    • Patients receiving or not receiving medication at present
  3. Patients giving voluntary written consent to participate in the study
  4. Male or female patients at 20 years or older

Exclusion Criteria:

  1. Patients who administered rosuvastatin, atorvastatin or ezetimibe within three month at the registration
  2. Patients with severe hypertension (systolic blood pressure [SBP] ≥ 180 mmHg or diastolic blood pressure [DBP] ≥ 110 mmHg)
  3. Patients with type 1 diabetes
  4. Patients judged to have familial hypercholesterolemia
  5. Patients with a serum triglyceride level of ≥ 400 mg/dL
  6. Patients who had the onset of cardiovascular or cerebrovascular disease within three months
  7. Patients with serious heart failure (NYHA classification III - IV)
  8. Patients with a history of hypersensitivity to statins
  9. Patients with a history of drug-induced myopathy
  10. Patients with severe complication of diabetes
  11. Patients receiving insulin
  12. Patients with serious liver or kidney disease
  13. Patients with serious concurrent disease such as malignancy, or patients with severely limited lifespan
  14. Patients who are or may be pregnant
  15. Patients judged by the investigators to be ineligible for participation in the study for any other reason

Sites / Locations

  • Hiramitsu Heart Clinic
  • Honjo Daiichi Hospital
  • Iryouhoujin Syadan Yanagisawakai Yanagisawa Iin
  • Matsuno Medical Clinic
  • Ishite Matsumoto Naika Junkanki Clinic
  • Ehime Medical CO OP Izumigawa Clinic
  • Fukui Chuoh Clinic
  • Fukuoka City Medical Association Hospital
  • Matsumoto Clinic
  • Saku Hospital
  • Soejima Medical Clinic
  • Takei's Clinic Internal Medicine
  • Nakamura Cardiovascular Clinic
  • Morizono Naika
  • Seino Internal Medicine Clinic
  • Kawade Iin
  • Hashimoto Naika Clinic
  • Iinuma Iin
  • Ishimura Clinic
  • Kawai Clinic
  • Niimi Clinic
  • Takai Clinic
  • Kobayashi Internal Medicine
  • Horibe Clinic
  • Kondo Cardiovascular Clinic
  • Yoshida Naika
  • Kogure Clinic
  • Nakano Clinic
  • Yoshii Central Clinic
  • Shigenobu Clinic
  • Takahashi Kiyohito Clinic
  • Hokuto Internal Medicine Clinic
  • Katsuya Clinic
  • Nakatani Hospital
  • Kosumo Clinic
  • Harima Clinic
  • Kusunose Clinic
  • Yanagi Medical Clinic
  • Okyozuka Clinic
  • Doniwa Clinic
  • Wakasa Medical Clinic
  • Association Medical Corporation Neurology Internal Medicine Kanamori Clinic
  • Medical Corporation Kuon-kai Kamata Medical Clinic
  • Kagawa Clinic
  • Hasegawa Outpatients Clinic for Cardiovascular Disease
  • Tempozan Naika Clinic
  • Kashiwagi Clinic
  • Hayashi Diabetes Clinic
  • Takada Internal Medicine Clinic
  • Iroden Clinic
  • Nagasu Clinic
  • Kobayashi Hospital
  • Hakuai Iin
  • Yamamoto Clinic
  • Arima Clinic
  • Kikuchi Clinic
  • Miho cho Cardiovascular Medical Clinic
  • Minamisawa Clinic
  • Shimokurata Heart Clinic
  • Yokohama Sotetsu Bldg. Clinic of Internal Medicine
  • Jinnouchi Clinic Diabetes Care Center
  • Maki Cardiovascular Clinic
  • Munakata Clinic
  • Terao Hospital
  • Higashi Diabetes and Cardiovascular Clinic
  • Matsuo Clinic
  • Miyagi Clinic Cardiovascular Medicine
  • Sawai Naika Iin
  • Asamoto Internal Medical Clinic
  • Ijinkai Takeda General Hospital
  • Koseikai Clinic
  • Sakabe International Clinic
  • Takenaka Clinic
  • Tegoshi Clinic
  • Iwasaki Hospital
  • Ishikawa Clinic
  • Yokota Naika
  • Etou Clinic
  • Kawano Clinic
  • Yamaguchi Clinic
  • Hasegawa Clinic
  • Nara Prefectural Gojo Hospital
  • Fujii Internal Medicine Clinic
  • Matsuoka Clinic
  • Ote Clinic of Internal
  • Uchiyama Clinic
  • Inoue Clinic
  • Maeda Medical Clinic
  • Nishimura Clinic
  • Shoseikai Matsuda Iin
  • Ikeda Clinic
  • Kanazawa Clinic
  • Fukuda Clinic
  • Jikuhara Clinic
  • Kawagishi-naika Clinic
  • Kinugawa Cardiology Clinic
  • Kubota Clinic
  • Masaki Clinic
  • Nanko Clinic
  • Osaka Ekisaikai Hospital
  • Tamatani Clinic
  • Hayashi Clinic
  • Nakao Medical Clinic
  • Saga Memorial Clinic
  • Enomoto Clinic
  • Asano Internal Medicine Clinic
  • Iryohojin Hogi Sinryojyo
  • Tokutake Iin
  • Medical Corporation Shibuya Clinic
  • Tanaka Medical Clinic
  • Yoshimura Eye&Internal Medical Clinic
  • Shizuoka Municipal Hospital
  • Takada Clinic
  • Murakami Clinic
  • Ota Clinic
  • Arizumi Clinic
  • Yuki National Health Insurance Hospital of Minami Town
  • Sekishinkan Hospital
  • Iryohojin Tokujikai Tanaka Iin
  • Kensei Uchimachi Clinic
  • Yata Clinic
  • Tokyo Center Clinic
  • Okudo Poly Clinic
  • Nakano Sunbright Clinic
  • Sugawara Clinic
  • Tsurumachi Clinic
  • Oda Clinic
  • Ishii Clinic
  • Ayame Medical Clinic
  • Matsuda Medical Clinic
  • Mizumachi Medical Clinic
  • Kuroda Iin
  • Yasue Naika

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Atorvastatin administration group

Rosuvastatin administration group

Arm Description

Outcomes

Primary Outcome Measures

Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level
Change in HbA1c Level

Secondary Outcome Measures

Occurrence of Deterioration of Diabetic Treatment Status
"Deterioration of diabetic treatment status" is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of > 0.5%.
Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status
"Deterioration of diabetic treatment status" is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of > 0.5%.
Percent Change in 1,5-AG Level
An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa
Change in HbA1c Level
Percent Change in Blood Glucose Level (Fasting)
Change in Blood Glucose Level (Fasting)
Percent Change in Insulin Level
An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa.
Change From Baseline in Insulin Level
An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa
Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)
Frequency of Serious Adverse Events (SAE)
Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)
Percent Change in Non-HDL-C Level
Percent Changes in Lipids and Inflammatory Marker (Hs-CRP) and Their Correlation
Correlation between percent changes in lipids (LDL-C, HDL-C, non-HDL-C, TG, non-HDL-C/HDL-C ratio, LDL-C/HDL-C ratio, TC and FFA) and inflammatory marker (hs-CRP)
Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007
Percentage of participants achieving the target LDL-C levels <100 mg/dL for participants with history of coronary artery diseases (CAD) and <120 mg/dL for participants without history of CAD are presented.
Change From Baseline in 1,5-AG Level
An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa

Full Information

First Posted
February 23, 2012
Last Updated
March 4, 2015
Sponsor
Listen Trial Group
search

1. Study Identification

Unique Protocol Identification Number
NCT01544309
Brief Title
LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
Acronym
LISTEN
Official Title
Study on Effect of Highly Potent Statins on Lipid Lowering Effect and Glucose Metabolism in Hypercholesterolemia Patients With Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Listen Trial Group

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to compare the effect of rosuvastatin and atorvastatin on lipid lowering effect and glucose metabolism in hypercholesterolemia patients with diabetes mellitus.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypercholesterolemia With Concomitant Type 2 Diabetes

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
1049 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Atorvastatin administration group
Arm Type
Experimental
Arm Title
Rosuvastatin administration group
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
Atorvastatin
Other Intervention Name(s)
Lipitor
Intervention Description
Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months. (When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)
Intervention Type
Drug
Intervention Name(s)
Rosuvastatin
Other Intervention Name(s)
Crestor
Intervention Description
Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months. (When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)
Primary Outcome Measure Information:
Title
Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level
Time Frame
Baseline, and 12 months after administration
Title
Change in HbA1c Level
Time Frame
Baseline, 12 months after administration
Secondary Outcome Measure Information:
Title
Occurrence of Deterioration of Diabetic Treatment Status
Description
"Deterioration of diabetic treatment status" is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of > 0.5%.
Time Frame
Baseline, 12 months after administration
Title
Number of Participants Stratified by Time to the Occurrence of Deterioration of Diabetic Treatment Status
Description
"Deterioration of diabetic treatment status" is defined as addition of new drug, increase in dosage, drug changes (therapy intensification), and deterioration in HbA1c of > 0.5%.
Time Frame
Baseline, 3, 6, 12 months after administration
Title
Percent Change in 1,5-AG Level
Description
An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）
Title
Change in HbA1c Level
Time Frame
Baseline, 3, 6 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）
Title
Percent Change in Blood Glucose Level (Fasting)
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）
Title
Change in Blood Glucose Level (Fasting)
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）
Title
Percent Change in Insulin Level
Description
An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa.
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）
Title
Change From Baseline in Insulin Level
Description
An inverse relationship exists between mean change in insulin level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment （or at the occurrence of deterioration of diabetic treatment status）
Title
Frequency of Cardiovascular Events (Coronary Artery Disease, Heart Failure, Cerebrovascular Disease, Peripheral Artery Disease and Aortic Disease)
Time Frame
From the start of the treatment to the end of study treatment
Title
Frequency of Serious Adverse Events (SAE)
Time Frame
Up to 12 months
Title
Percent Changes in Lipids (LDL-C, HDL-C, TC, TG, Non-HDL-C/HDL-C Ratio, and FFA)
Time Frame
Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment
Title
Percent Change in Non-HDL-C Level
Time Frame
Baseline, 3 and 6 months after administration, the end of starting dose and the end of study treatment
Title
Percent Changes in Lipids and Inflammatory Marker (Hs-CRP) and Their Correlation
Description
Correlation between percent changes in lipids (LDL-C, HDL-C, non-HDL-C, TG, non-HDL-C/HDL-C ratio, LDL-C/HDL-C ratio, TC and FFA) and inflammatory marker (hs-CRP)
Time Frame
Baseline, 3, 6, 12 months after administration, the end of starting dose and the end of study treatment
Title
Rate of Patients Who Have Reached the Target LDL-C Level Specified in Japan Atherosclerosis Society Guidelines (JASGL) 2007
Description
Percentage of participants achieving the target LDL-C levels <100 mg/dL for participants with history of coronary artery diseases (CAD) and <120 mg/dL for participants without history of CAD are presented.
Time Frame
3 months after administration, the end of starting dose and the end of study treatment
Title
Change From Baseline in 1,5-AG Level
Description
An inverse relationship exists between mean change in 1,5-AG level and the mean rate of change when the degree of standard deviation is large, wherein the mean change is negative although the mean rate of change is positive or vice versa
Time Frame
Baseline, 3, 6, 12 months after administration and the end of study treatment（or at the occurrence of deterioration of diabetic treatment status）

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Hypercholesterolemia patients • Patients who have not achieved the target control levels of LDL-C in the "Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2007" Type 2 diabetes patients Patients diagnosed with type 2 diabetes and receiving diet therapy, exercise therapy, or medication Patients who received constant therapy for three months before registration and have no plan for therapy change Patients with kept HbA1c level (Japan Diabetes Society [JDS] level) of less than 7.0% (or, National Glycohemoglobin Standardization Program [NGSP] level of less than 7.4%) within three months before registration Patients receiving or not receiving medication at present Patients giving voluntary written consent to participate in the study Male or female patients at 20 years or older Exclusion Criteria: Patients who administered rosuvastatin, atorvastatin or ezetimibe within three month at the registration Patients with severe hypertension (systolic blood pressure [SBP] ≥ 180 mmHg or diastolic blood pressure [DBP] ≥ 110 mmHg) Patients with type 1 diabetes Patients judged to have familial hypercholesterolemia Patients with a serum triglyceride level of ≥ 400 mg/dL Patients who had the onset of cardiovascular or cerebrovascular disease within three months Patients with serious heart failure (NYHA classification III - IV) Patients with a history of hypersensitivity to statins Patients with a history of drug-induced myopathy Patients with severe complication of diabetes Patients receiving insulin Patients with serious liver or kidney disease Patients with serious concurrent disease such as malignancy, or patients with severely limited lifespan Patients who are or may be pregnant Patients judged by the investigators to be ineligible for participation in the study for any other reason
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hisao Ogawa, Ph.D
Organizational Affiliation
Department of Cardiovascular Medicine, Faculty of Life Sciences, Kumamoto University
Official's Role
Study Chair
Facility Information:
Facility Name
Hiramitsu Heart Clinic
City
Nagoya city
State/Province
Aichi pref.
Country
Japan
Facility Name
Honjo Daiichi Hospital
City
Yurihonjo city
State/Province
Akita pref.
Country
Japan
Facility Name
Iryouhoujin Syadan Yanagisawakai Yanagisawa Iin
City
Matsudo city
State/Province
Chiba pref.
Country
Japan
Facility Name
Matsuno Medical Clinic
City
Iyo gun
State/Province
Ehime pref.
Country
Japan
Facility Name
Ishite Matsumoto Naika Junkanki Clinic
City
Matsuyama city
State/Province
Ehime pref.
Country
Japan
Facility Name
Ehime Medical CO OP Izumigawa Clinic
City
Niihama city
State/Province
Ehime pref.
Country
Japan
Facility Name
Fukui Chuoh Clinic
City
Fukui city
State/Province
Fukui pref.
Country
Japan
Facility Name
Fukuoka City Medical Association Hospital
City
Fukuoka city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Matsumoto Clinic
City
Fukuoka city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Saku Hospital
City
Fukuoka city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Soejima Medical Clinic
City
Fukuoka city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Takei's Clinic Internal Medicine
City
Fukuoka city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Nakamura Cardiovascular Clinic
City
Itoshima city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Morizono Naika
City
Kitakyushu city
State/Province
Fukuoka pref.
Country
Japan
Facility Name
Seino Internal Medicine Clinic
City
Koriyama city
State/Province
Fukushima pref.
Country
Japan
Facility Name
Kawade Iin
City
Gifu city
State/Province
Gifu pref.
ZIP/Postal Code
Japan
Country
Japan
Facility Name
Hashimoto Naika Clinic
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Iinuma Iin
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Ishimura Clinic
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Kawai Clinic
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Niimi Clinic
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Takai Clinic
City
Gifu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Kobayashi Internal Medicine
City
Kakamigahara city
State/Province
Gifu pref.
Country
Japan
Facility Name
Horibe Clinic
City
Motosu city
State/Province
Gifu pref.
Country
Japan
Facility Name
Kondo Cardiovascular Clinic
City
Ogaki
State/Province
Gifu pref.
Country
Japan
Facility Name
Yoshida Naika
City
Ogaki
State/Province
Gifu pref.
Country
Japan
Facility Name
Kogure Clinic
City
Maebashi city
State/Province
Gunma pref.
Country
Japan
Facility Name
Nakano Clinic
City
Shibukawa city
State/Province
Gunma pref.
Country
Japan
Facility Name
Yoshii Central Clinic
City
Takasaki city
State/Province
Gunma pref.
Country
Japan
Facility Name
Shigenobu Clinic
City
Miyoshi city
State/Province
Hiroshima pref.
Country
Japan
Facility Name
Takahashi Kiyohito Clinic
City
Hakodate city
State/Province
Hokkaido pref.
Country
Japan
Facility Name
Hokuto Internal Medicine Clinic
City
Sapporo city
State/Province
Hokkaido pref.
Country
Japan
Facility Name
Katsuya Clinic
City
Amagasaki city
State/Province
Hyogo pref.
Country
Japan
Facility Name
Nakatani Hospital
City
Himeji city
State/Province
Hyogo pref.
Country
Japan
Facility Name
Kosumo Clinic
City
Kako gun
State/Province
Hyogo pref.
Country
Japan
Facility Name
Harima Clinic
City
Kakogawa
State/Province
Hyogo pref.
Country
Japan
Facility Name
Kusunose Clinic
City
Kobe city
State/Province
Hyogo pref.
Country
Japan
Facility Name
Yanagi Medical Clinic
City
Hakusan city
State/Province
Ishikawa pref.
Country
Japan
Facility Name
Okyozuka Clinic
City
Ishikawa gun
State/Province
Ishikawa pref.
Country
Japan
Facility Name
Doniwa Clinic
City
Kanazawa city
State/Province
Ishikawa pref.
Country
Japan
Facility Name
Wakasa Medical Clinic
City
Kanazawa city
State/Province
Ishikawa pref.
Country
Japan
Facility Name
Association Medical Corporation Neurology Internal Medicine Kanamori Clinic
City
Iwate gun
State/Province
Iwate pref.
Country
Japan
Facility Name
Medical Corporation Kuon-kai Kamata Medical Clinic
City
Morioka city
State/Province
Iwate pref.
Country
Japan
Facility Name
Kagawa Clinic
City
Marugame city
State/Province
Kagawa pref.
Country
Japan
Facility Name
Hasegawa Outpatients Clinic for Cardiovascular Disease
City
Takamatsu city
State/Province
Kagawa pref.
Country
Japan
Facility Name
Tempozan Naika Clinic
City
Kagoshima city
State/Province
Kagoshima pref.
Country
Japan
Facility Name
Kashiwagi Clinic
City
Ayase city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Hayashi Diabetes Clinic
City
Chigasaki city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Takada Internal Medicine Clinic
City
Hiratsuka city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Iroden Clinic
City
Kamakura city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Nagasu Clinic
City
Kamakura city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Kobayashi Hospital
City
Odawara city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Hakuai Iin
City
Sagamihara city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Yamamoto Clinic
City
Sagamihara city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Arima Clinic
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Kikuchi Clinic
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Miho cho Cardiovascular Medical Clinic
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Minamisawa Clinic
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Shimokurata Heart Clinic
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Yokohama Sotetsu Bldg. Clinic of Internal Medicine
City
Yokohama city
State/Province
Kanagawa pref.
Country
Japan
Facility Name
Jinnouchi Clinic Diabetes Care Center
City
Kumamoto city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Maki Cardiovascular Clinic
City
Kumamoto city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Munakata Clinic
City
Kumamoto city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Terao Hospital
City
Kumamoto city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Higashi Diabetes and Cardiovascular Clinic
City
Tamana city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Matsuo Clinic
City
Tamana city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Miyagi Clinic Cardiovascular Medicine
City
Yatsushiro city
State/Province
Kumamoto pref.
Country
Japan
Facility Name
Sawai Naika Iin
City
Kyotanabe city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Asamoto Internal Medical Clinic
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Ijinkai Takeda General Hospital
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Koseikai Clinic
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Sakabe International Clinic
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Takenaka Clinic
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Tegoshi Clinic
City
Kyoto city
State/Province
Kyoto pref.
Country
Japan
Facility Name
Iwasaki Hospital
City
Tsu city
State/Province
Mie pref.
Country
Japan
Facility Name
Ishikawa Clinic
City
Miyazaki city
State/Province
Miyazaki pref.
Country
Japan
Facility Name
Yokota Naika
City
Miyazaki city
State/Province
Miyazaki pref.
Country
Japan
Facility Name
Etou Clinic
City
Nichinan city
State/Province
Miyazaki pref.
Country
Japan
Facility Name
Kawano Clinic
City
Nichinan city
State/Province
Miyazaki pref.
Country
Japan
Facility Name
Yamaguchi Clinic
City
Nichinan city
State/Province
Miyazaki pref.
Country
Japan
Facility Name
Hasegawa Clinic
City
Nakano city
State/Province
Nagano pref.
Country
Japan
Facility Name
Nara Prefectural Gojo Hospital
City
Gojo city
State/Province
Nara pref.
Country
Japan
Facility Name
Fujii Internal Medicine Clinic
City
Kashihara city
State/Province
Nara pref.
Country
Japan
Facility Name
Matsuoka Clinic
City
Kita katsuragi gun
State/Province
Nara pref.
Country
Japan
Facility Name
Ote Clinic of Internal
City
Sakurai city
State/Province
Nara pref.
Country
Japan
Facility Name
Uchiyama Clinic
City
Joetsu city
State/Province
Niigata pref.
Country
Japan
Facility Name
Inoue Clinic
City
Niigata city
State/Province
Niigata pref.
Country
Japan
Facility Name
Maeda Medical Clinic
City
Niigata city
State/Province
Niigata pref.
Country
Japan
Facility Name
Nishimura Clinic
City
Fujiidera city
State/Province
Osaka pref.
Country
Japan
Facility Name
Shoseikai Matsuda Iin
City
Fujiidera city
State/Province
Osaka pref.
Country
Japan
Facility Name
Ikeda Clinic
City
Higashiosaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Kanazawa Clinic
City
Izumi city
State/Province
Osaka pref.
Country
Japan
Facility Name
Fukuda Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Jikuhara Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Kawagishi-naika Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Kinugawa Cardiology Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Kubota Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Masaki Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Nanko Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Osaka Ekisaikai Hospital
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Tamatani Clinic
City
Osaka city
State/Province
Osaka pref.
Country
Japan
Facility Name
Hayashi Clinic
City
Sakai city
State/Province
Osaka pref.
Country
Japan
Facility Name
Nakao Medical Clinic
City
Sakai city
State/Province
Osaka pref.
Country
Japan
Facility Name
Saga Memorial Clinic
City
Saga city
State/Province
Saga pref.
Country
Japan
Facility Name
Enomoto Clinic
City
Ageo city
State/Province
Saitama pref.
Country
Japan
Facility Name
Asano Internal Medicine Clinic
City
Kawagoe city
State/Province
Saitama pref.
Country
Japan
Facility Name
Iryohojin Hogi Sinryojyo
City
Kawaguchi city
State/Province
Saitama pref.
Country
Japan
Facility Name
Tokutake Iin
City
Kawaguchi city
State/Province
Saitama pref.
Country
Japan
Facility Name
Medical Corporation Shibuya Clinic
City
Kumagaya city
State/Province
Saitama pref.
Country
Japan
Facility Name
Tanaka Medical Clinic
City
Saitama city
State/Province
Saitama pref.
Country
Japan
Facility Name
Yoshimura Eye&Internal Medical Clinic
City
Mishima city
State/Province
Shizuoka pref.
Country
Japan
Facility Name
Shizuoka Municipal Hospital
City
Shizuoka city
State/Province
Shizuoka pref.
Country
Japan
Facility Name
Takada Clinic
City
Tochigi city
State/Province
Tochigi pref.
Country
Japan
Facility Name
Murakami Clinic
City
Anan city
State/Province
Tokushima pref.
Country
Japan
Facility Name
Ota Clinic
City
Awa city
State/Province
Tokushima pref.
Country
Japan
Facility Name
Arizumi Clinic
City
Itano gun
State/Province
Tokushima pref.
Country
Japan
Facility Name
Yuki National Health Insurance Hospital of Minami Town
City
Kaifu gun
State/Province
Tokushima pref.
Country
Japan
Facility Name
Sekishinkan Hospital
City
Komatsushima city
State/Province
Tokushima pref.
Country
Japan
Facility Name
Iryohojin Tokujikai Tanaka Iin
City
Myozai gun
State/Province
Tokushima pref.
Country
Japan
Facility Name
Kensei Uchimachi Clinic
City
Tokushima city
State/Province
Tokushima pref.
Country
Japan
Facility Name
Yata Clinic
City
Yoshinogawa city
State/Province
Tokushima pref.
Country
Japan
Facility Name
Tokyo Center Clinic
City
Chuo ku
State/Province
Tokyo
Country
Japan
Facility Name
Okudo Poly Clinic
City
Katsushika ku
State/Province
Tokyo
Country
Japan
Facility Name
Nakano Sunbright Clinic
City
Nakano ku
State/Province
Tokyo
Country
Japan
Facility Name
Sugawara Clinic
City
Nerima ku
State/Province
Tokyo
Country
Japan
Facility Name
Tsurumachi Clinic
City
Setagaya ku
State/Province
Tokyo
Country
Japan
Facility Name
Oda Clinic
City
Shinjuku ku
State/Province
Tokyo
Country
Japan
Facility Name
Ishii Clinic
City
Tachikawa city
State/Province
Tokyo
Country
Japan
Facility Name
Ayame Medical Clinic
City
Shimonoseki city
State/Province
Yamaguchi pref.
Country
Japan
Facility Name
Matsuda Medical Clinic
City
Shimonoseki city
State/Province
Yamaguchi pref.
Country
Japan
Facility Name
Mizumachi Medical Clinic
City
Shimonoseki city
State/Province
Yamaguchi pref.
Country
Japan
Facility Name
Kuroda Iin
City
Otsuki city
State/Province
Yamanashi pref.
Country
Japan
Facility Name
Yasue Naika
City
Gifu city
Country
Japan

12. IPD Sharing Statement

Citations:
PubMed Identifier
25186922
Citation
Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, Sugawara M, Masuda I, Mori H, Waki M, Yoshiyama M, Watada H. Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients (LISTEN) study -. Circ J. 2014;78(10):2512-5. doi: 10.1253/circj.cj-14-0810. Epub 2014 Sep 2.
Results Reference
derived

Learn more about this trial

LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts

We'll reach out to this number within 24 hrs